These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 29507611)

  • 1. Dapagliflozin improves treatment satisfaction in overweight patients with type 2 diabetes mellitus: a patient reported outcome study (PRO study).
    Nakajima H; Okada S; Mohri T; Kanda E; Inaba N; Hirasawa Y; Seino H; Kuroda H; Hiyoshi T; Niiya T; Ishii H
    Diabetol Metab Syndr; 2018; 10():11. PubMed ID: 29507611
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trial.
    Frías JP; Guja C; Hardy E; Ahmed A; Dong F; Öhman P; Jabbour SA
    Lancet Diabetes Endocrinol; 2016 Dec; 4(12):1004-1016. PubMed ID: 27651331
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized trial of dapagliflozin and metformin, alone and combined, in overweight women after gestational diabetes mellitus.
    Elkind-Hirsch KE; Seidemann E; Harris R
    Am J Obstet Gynecol MFM; 2020 Aug; 2(3):100139. PubMed ID: 33345876
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized, Double-Blind, Phase 3 Trial of Triple Therapy With Dapagliflozin Add-on to Saxagliptin Plus Metformin in Type 2 Diabetes.
    Mathieu C; Ranetti AE; Li D; Ekholm E; Cook W; Hirshberg B; Chen H; Hansen L; Iqbal N
    Diabetes Care; 2015 Nov; 38(11):2009-17. PubMed ID: 26246458
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes.
    Lambers Heerspink HJ; de Zeeuw D; Wie L; Leslie B; List J
    Diabetes Obes Metab; 2013 Sep; 15(9):853-62. PubMed ID: 23668478
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Humalog Mix 25 in patients with type 2 diabetes which do not achieve acceptable glycemic control with oral agents: results from a phase III, randomized, parallel study.
    Tîrgovişte CI; Străchinariu R; Farcaşiu E; Milicevic Z; Teodorescu G
    Rom J Intern Med; 2003; 41(2):153-62. PubMed ID: 15526500
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of sodium-glucose co-transporter-2 inhibitors on the levels of serum asprosin in patients with newly diagnosed type 2 diabetes mellitus.
    Jiang A; Feng Z; Yuan L; Zhang Y; Li Q; She Y
    Diabetol Metab Syndr; 2021 Mar; 13(1):34. PubMed ID: 33766125
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Changes in weight loss-related quality of life among type 2 diabetes mellitus patients treated with dapagliflozin.
    Grandy S; Hashemi M; Langkilde AM; Parikh S; Sjöström CD
    Diabetes Obes Metab; 2014 Jul; 16(7):645-50. PubMed ID: 24443876
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dapagliflozin improves glycemic control and reduces body weight as add-on therapy to metformin plus sulfonylurea: a 24-week randomized, double-blind clinical trial.
    Matthaei S; Bowering K; Rohwedder K; Grohl A; Parikh S;
    Diabetes Care; 2015 Mar; 38(3):365-72. PubMed ID: 25592197
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dapagliflozin added to usual care in individuals with type 2 diabetes mellitus with preexisting cardiovascular disease: a 24-week, multicenter, randomized, double-blind, placebo-controlled study with a 28-week extension.
    Leiter LA; Cefalu WT; de Bruin TW; Gause-Nilsson I; Sugg J; Parikh SJ
    J Am Geriatr Soc; 2014 Jul; 62(7):1252-62. PubMed ID: 24890683
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Durability of glycaemic efficacy over 2 years with dapagliflozin versus glipizide as add-on therapies in patients whose type 2 diabetes mellitus is inadequately controlled with metformin.
    Nauck MA; Del Prato S; Durán-García S; Rohwedder K; Langkilde AM; Sugg J; Parikh SJ
    Diabetes Obes Metab; 2014 Nov; 16(11):1111-20. PubMed ID: 24919526
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of dapagliflozin on glycaemic control and other cardiovascular disease risk factors in type 2 diabetes mellitus: a real-world observational study.
    McGurnaghan SJ; Brierley L; Caparrotta TM; McKeigue PM; Blackbourn LAK; Wild SH; Leese GP; McCrimmon RJ; McKnight JA; Pearson ER; Petrie JR; Sattar N; Colhoun HM;
    Diabetologia; 2019 Apr; 62(4):621-632. PubMed ID: 30631892
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of Dapagliflozin on Body Composition and Liver Tests in Patients with Nonalcoholic Steatohepatitis Associated with Type 2 Diabetes Mellitus: A Prospective, Open-label, Uncontrolled Study.
    Tobita H; Sato S; Miyake T; Ishihara S; Kinoshita Y
    Curr Ther Res Clin Exp; 2017; 87():13-19. PubMed ID: 28912902
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin.
    Bolinder J; Ljunggren Ö; Kullberg J; Johansson L; Wilding J; Langkilde AM; Sugg J; Parikh S
    J Clin Endocrinol Metab; 2012 Mar; 97(3):1020-31. PubMed ID: 22238392
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Triple therapy with low-dose dapagliflozin plus saxagliptin versus dual therapy with each monocomponent, all added to metformin, in uncontrolled type 2 diabetes.
    Rosenstock J; Perl S; Johnsson E; García-Sánchez R; Jacob S
    Diabetes Obes Metab; 2019 Sep; 21(9):2152-2162. PubMed ID: 31144431
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dapagliflozin efficacy and safety: a perspective review.
    Anderson SL
    Ther Adv Drug Saf; 2014 Dec; 5(6):242-54. PubMed ID: 25436106
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Empagliflozin versus dapagliflozin in patients with type 2 diabetes inadequately controlled with metformin, glimepiride and dipeptidyl peptide 4 inhibitors: A 52-week prospective observational study.
    Ku EJ; Lee DH; Jeon HJ; Oh TK
    Diabetes Res Clin Pract; 2019 May; 151():65-73. PubMed ID: 30954510
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The efficacy of dapagliflozin combined with hypoglycemic drugs in treating type 2 diabetes: protocol for meta-analysis of randomized controlled trials.
    Sun YN; Zhou Y; Chen X; Che WS; Leung SW
    Syst Rev; 2013 Nov; 2():103. PubMed ID: 24225054
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Baseline low-density lipoprotein cholesterol predicts the hemoglobin A1c-lowering effect of dapagliflozin in Japanese patients with type 2 diabetes mellitus.
    Iwasaki T; Yoneda M
    Diabetol Int; 2016 Mar; 7(1):77-82. PubMed ID: 30603246
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dapagliflozin: a novel sodium-glucose cotransporter type 2 inhibitor for the treatment of type 2 diabetes mellitus.
    Shah NK; Deeb WE; Choksi R; Epstein BJ
    Pharmacotherapy; 2012 Jan; 32(1):80-94. PubMed ID: 22392830
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.